The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China
Jianlin Xu,1,* Guozheng Ding,2,* Xueyan Zhang,1 Bo Jin,1 Yuqing Lou,1 Yanwei Zhang,1 Huiming Wang,1 Dan Wu,3 Baohui Han1 1Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China; 2Department of Pulmonary, Anqing Municipal Hospi...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-10-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/the-egfr-tyrosine-kinase-inhibitors-as-second-line-therapy-for-egfr-wi-peer-reviewed-article-OTT |